495 related articles for article (PubMed ID: 29035367)
1. Targeting glioma stem cells through combined BMI1 and EZH2 inhibition.
Jin X; Kim LJY; Wu Q; Wallace LC; Prager BC; Sanvoranart T; Gimple RC; Wang X; Mack SC; Miller TE; Huang P; Valentim CL; Zhou QG; Barnholtz-Sloan JS; Bao S; Sloan AE; Rich JN
Nat Med; 2017 Nov; 23(11):1352-1361. PubMed ID: 29035367
[TBL] [Abstract][Full Text] [Related]
2. DHHC protein family targets different subsets of glioma stem cells in specific niches.
Chen X; Hu L; Yang H; Ma H; Ye K; Zhao C; Zhao Z; Dai H; Wang H; Fang Z
J Exp Clin Cancer Res; 2019 Jan; 38(1):25. PubMed ID: 30658672
[TBL] [Abstract][Full Text] [Related]
3. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
[TBL] [Abstract][Full Text] [Related]
4. BMI1 sustains human glioblastoma multiforme stem cell renewal.
Abdouh M; Facchino S; Chatoo W; Balasingam V; Ferreira J; Bernier G
J Neurosci; 2009 Jul; 29(28):8884-96. PubMed ID: 19605626
[TBL] [Abstract][Full Text] [Related]
5. Targeting EZH2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway.
Zhao G; Deng Z; Li X; Wang H; Chen G; Feng M; Zhou Y
Exp Brain Res; 2023 Oct; 241(10):2409-2418. PubMed ID: 37644332
[TBL] [Abstract][Full Text] [Related]
6. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
[TBL] [Abstract][Full Text] [Related]
7. Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients.
Wu Z; Wang Q; Wang L; Li G; Liu H; Fan F; Li Z; Li Y; Tu Y
J Neurol Sci; 2013 Dec; 335(1-2):191-6. PubMed ID: 24139839
[TBL] [Abstract][Full Text] [Related]
8. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
9. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
10. Beyond EZH2: is the polycomb protein CBX2 an emerging target for anti-cancer therapy?
Jangal M; Lebeau B; Witcher M
Expert Opin Ther Targets; 2019 Jul; 23(7):565-578. PubMed ID: 31177918
[No Abstract] [Full Text] [Related]
11. Glioma stem cell maintenance: the role of the microenvironment.
Heddleston JM; Hitomi M; Venere M; Flavahan WA; Yang K; Kim Y; Minhas S; Rich JN; Hjelmeland AB
Curr Pharm Des; 2011; 17(23):2386-401. PubMed ID: 21827414
[TBL] [Abstract][Full Text] [Related]
12. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
[TBL] [Abstract][Full Text] [Related]
13. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.
Lee YC; Chang WW; Chen YY; Tsai YH; Chou YH; Tseng HC; Chen HL; Wu CC; Chang-Chien J; Lee HT; Yang HF; Wang BY
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914785
[TBL] [Abstract][Full Text] [Related]
14. Cell surface GRP78 regulates BACE2 via lysosome-dependent manner to maintain mesenchymal phenotype of glioma stem cells.
Chen Z; Wang H; Zhang Z; Xu J; Qi Y; Xue H; Gao Z; Zhao R; Wang S; Zhang S; Qiu W; Guo X; Li G
J Exp Clin Cancer Res; 2021 Jan; 40(1):20. PubMed ID: 33413577
[TBL] [Abstract][Full Text] [Related]
15. Stem cell signature in glioblastoma: therapeutic development for a moving target.
Nakano I
J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
[TBL] [Abstract][Full Text] [Related]
16. Polycomb complex mediated epigenetic reprogramming alters TGF-β signaling via a novel EZH2/miR-490/TGIF2 axis thereby inducing migration and EMT potential in glioblastomas.
Vinchure OS; Sharma V; Tabasum S; Ghosh S; Singh RP; Sarkar C; Kulshreshtha R
Int J Cancer; 2019 Sep; 145(5):1254-1269. PubMed ID: 31008529
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.
Kim E; Kim M; Woo DH; Shin Y; Shin J; Chang N; Oh YT; Kim H; Rheey J; Nakano I; Lee C; Joo KM; Rich JN; Nam DH; Lee J
Cancer Cell; 2013 Jun; 23(6):839-52. PubMed ID: 23684459
[TBL] [Abstract][Full Text] [Related]
18. Melatonin Inhibits Glioblastoma Stem-like cells through Suppression of EZH2-NOTCH1 Signaling Axis.
Zheng X; Pang B; Gu G; Gao T; Zhang R; Pang Q; Liu Q
Int J Biol Sci; 2017; 13(2):245-253. PubMed ID: 28255276
[TBL] [Abstract][Full Text] [Related]
19. NSG-70, a new glioblastoma cell line with mixed proneural-mesenchymal features, associates NOTCH1-WNT5A signaling with stem cell maintenance and angiogenesis.
Singh DK; Shivalingappa PKM; Sharma A; Mondal A; Muzumdar D; Shiras A; Bapat SA
J Neurooncol; 2022 May; 157(3):575-591. PubMed ID: 35430703
[TBL] [Abstract][Full Text] [Related]
20. Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting.
Balasubramaniyan V; Vaillant B; Wang S; Gumin J; Butalid ME; Sai K; Mukheef F; Kim SH; Boddeke HW; Lang F; Aldape K; Sulman EP; Bhat KP; Colman H
Oncotarget; 2015 Oct; 6(31):31007-17. PubMed ID: 26307681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
